Novel antibacterial agents are critically needed in light of the constant menace posed by bacterial infections and subsequent emergence of antibiotic-resistant strains. Quality of life has been improved remarkably through antibiotics that have fought microbial pathogens. . Luteolin has shown effectiveness against both gram-positive and gram negative bacteria. Luteolin and its derivatives, as novel phytochemical antimicrobial agents, exhibit activity against both Gram-positive and Gram-negative bacteria . Luteolin target bacteria by disrupting their cell membranes, inhibiting nucleic acid synthesis, and interfering with key enzymes. It also blocks quorum sensing and biofilm formation, crucial for bacterial virulence and resistance. Luteolin, despite its therapeutic potential, has limited clinical use due to poor water solubility and low bioavailability, leading to reduced absorption and rapid metabolism in the body. To address these issues, researchers are exploring advanced formulations like nanoparticles and liposomes to improve its solubility and effectiveness. Recent formulation advancements aim to enhance luteolin's delivery and efficacy as an antibacterial agent. However, in-depth in vivo studies are essential to unlock its full therapeutic potential for clinical use. This review highlights luteolin's antibacterial capabilities, usage challenges, and recent progress, stressing the importance of further research to fully leverage its benefits.
No takes yet. Share an insight, caveat, or question.
Rajagopal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: